PillRx only · Tablet · Sublingual
Asenapine Maleate
Brands: Asenapine · Saphris · Asenapine Maleate
3 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US13 NDCs
3 active makers
3 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 6 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$11.969
Latest avg · Jul 22, 2026
+5%
Since Dec 17, 2025
3
Active US suppliers
77%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
11K
Rx · 2026 Q1
556K
Units dispensed
-16%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it3 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Breckenridge Pharmaceutical, Inc. | unknown | 10 | SUPPLYING |
| Allergan, Inc. | unknown | 7 | SUPPLYING |
| MSN Laboratories Private Limited | unknown | 5 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- May 18, 2017RECALLRecall (Class II): Saphris 10 mg (asenapine) sublingual tablets, 6x10 count blister packs, Rx only, Black Cherry Flavor, Manufactured by: …
Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets — Recalling firm: Forest Laboratories, LLC — Nationwide